DAVID ASH: Open Payments
NPI 1295110542 · GLADSTONE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,755 in 160 payments from 20 companies in 2025. Trend: 2023 $2,171 · 2024 $2,864 · 2025 $2,755
Food & beverage: $2,755
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $512 |
| Otsuka America Pharmaceutical, Inc. | 18 | $305 |
| Vanda Pharmaceuticals Inc. | 14 | $290 |
| Neurocrine BioSciences, Inc. | 15 | $264 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $219 |
| Teva Pharmaceuticals USA, Inc. | 13 | $197 |
| Supernus Pharmaceuticals, Inc. | 20 | $152 |
| Bausch Health US, LLC | 5 | $119 |
| Janssen Pharmaceuticals, Inc | 4 | $106 |
| Lundbeck LLC | 4 | $92 |
Products named: VRAYLAR, REXULTI, INGREZZA, CAPLYTA, FANAPT, AUSTEDO XR, Qelbree, APLENZIN.
Industry payments across MO — which companies pay providers there.
